Galectin Therapeutics Inc (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH81909D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

64

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company provides products such as GR-MD-02, GM-CT-01, and others. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. Its GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. Galectin Therapeutics provides research, study of science of galectin proteins, and others. The company's products are used to treat fibrosis, galectin effects on liver fibrosis and lung fibrosis, among others. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.

Galectin Therapeutics Inc (GALT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Galectin Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Galectin Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Galectin Forms Joint Venture With SBH Sciences 12

Galectin Therapeutics Enters Into Discovery Agreement With University of Georgia For Anti-Galectin Drugs 13

Equity Offering 14

Galectin Therapeutics Plans to Raise up to USD30 Million in Public Offering of Shares 14

Galectin Therapeutics Raises USD3 Million in Private Placement of Shares 15

Galectin Therapeutics Announces Secondary Offering of Shares 16

Galectin Therapeutics Prices Private Placement of Shares for USD9.8 Million 17

Galectin Therapeutics Completes Public Offering Of Common Stock For USD 24 Million 18

Galectin Therapeutics Completes Private Placement Of Shares For USD 3 Million Upon Exercise Of Warrants 19

Galectin Therapeutics Completes Private Placement Of Shares For USD 3 Million 20

Galectin Therapeutics Completes Public Offering Of Units For USD 12 Million 21

Galectin Therapeutics Inc-Key Competitors 22

Galectin Therapeutics Inc-Key Employees 23

Galectin Therapeutics Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Joint Venture 24

Recent Developments 25

Financial Announcements 25

Aug 14, 2018: Galectin Therapeutics reports 2018 second quarter financial results and provides business update 25

May 11, 2018: Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update 27

Mar 29, 2018: Galectin Therapeutics Reports 2017 Financial Results 29

Mar 29, 2018: Galectin Therapeutics Announces 2017 Financial Results 31

Nov 07, 2017: Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update 33

Aug 14, 2017: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 34

May 15, 2017: Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update 36

Mar 28, 2017: Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update 38

Corporate Communications 40

Sep 25, 2017: Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017 40

Sep 18, 2017: Galectin Therapeutics: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 41

Mar 23, 2017: Galectin Therapeutics Issues Statement Regarding GALTW and GALTU 42

Product News 43

12/04/2017: Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017 43

06/12/2018: Galectin Therapeutics Announces New CEO 44

04/18/2018: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018 45

03/14/2017: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema) 46

Clinical Trials 47

Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board 47

May 14, 2018: Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting 48

Apr 16, 2018: Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis 49

Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018 51

Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference 52

Dec 14, 2017: Galectin Therapeutics Provides Corporate Update at Annual Meeting 53

Dec 05, 2017: Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial 54

Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial 56

Oct 20, 2017: Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis 57

Sep 12, 2017: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02 58

Jun 13, 2017: Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial 59

Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017 60

Mar 06, 2017: Galectin's GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis 61

Feb 07, 2017: Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials 62

Feb 01, 2017: Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64


List of Figure

List of Figures

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Galectin Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List of Table

List of Tables

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Galectin Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Galectin Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Galectin Forms Joint Venture With SBH Sciences 12

Galectin Therapeutics Enters Into Discovery Agreement With University of Georgia For Anti-Galectin Drugs 13

Galectin Therapeutics Plans to Raise up to USD30 Million in Public Offering of Shares 14

Galectin Therapeutics Raises USD3 Million in Private Placement of Shares 15

Galectin Therapeutics Announces Secondary Offering of Shares 16

Galectin Therapeutics Prices Private Placement of Shares for USD9.8 Million 17

Galectin Therapeutics Completes Public Offering Of Common Stock For USD 24 Million 18

Galectin Therapeutics Completes Private Placement Of Shares For USD 3 Million Upon Exercise Of Warrants 19

Galectin Therapeutics Completes Private Placement Of Shares For USD 3 Million 20

Galectin Therapeutics Completes Public Offering Of Units For USD 12 Million 21

Galectin Therapeutics Inc, Key Competitors 22

Galectin Therapeutics Inc, Key Employees 23

Galectin Therapeutics Inc, Joint Venture 24

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022